IGC Pharma Announces Equity Analyst Coverage by Ascendiant with a “Buy” Recommendation and $3.00 Price Target
IGC Pharma, Inc. (IGC)
NASDAQ:AMEX Investor Relations:
igcinc.us/investor-center/overview
Company Research
Source: Business Wire
POTOMAC, Md.--(BUSINESS WIRE)--IGC Pharma, Inc. (“IGC Pharma,” “IGC,” or the “Company”) (NYSE American: IGC) announces that Ascendiant Capital Markets LLC (Ascendiant) has issued an analyst coverage research report on the Company’s common stock.All reports on IGC Pharma prepared by analysts represent the views of those analysts and are not necessarily those of IGC Pharma. IGC is not responsible for the content, accuracy, or timelines provided by analysts. By referring to these analysts or distributing their opinions, IGC does not in any way commit itself to the validity of such information, conclusions, or recommendations.A copy of the analyst report can be obtained directly from Ascendiant at https://ascendiant.com/research-reports/company/igc-pharma-inc/.About IGC Pharma Inc. (dba IGC):IGC Pharma is pursuing innovative solutions to fight Alzheimer's disease and related challenges. IGC Pharma's portfolio comprises five assets, all with a singular mission - to transform the landsc
Show less
Read more
Impact Snapshot
Event Time:
IGC
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IGC alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IGC alerts
High impacting IGC Pharma, Inc. news events
Weekly update
A roundup of the hottest topics
IGC
News
- IGC-AD1’s Interim Phase 2 Data Show a Reduction in Alzheimer’s Agitation at Week TwoBusiness Wire
- IGC Pharma Adds Advisor in Artificial IntelligenceBusiness Wire
- IGC Pharma Announces $3 Million Unregistered Private Placement of its Common StockBusiness Wire
- IGC Pharma Announces Positive Interim Results for IGC-AD1 in Reducing Alzheimer’s AgitationBusiness Wire
- IGC PHARMA Announces its Participation at the Benzinga Virtual Healthcare Summit 2024Business Wire
IGC
Sec Filings
- 5/3/24 - Form EFFECT
- 4/18/24 - Form S-3
- 4/5/24 - Form 8-K
- IGC's page on the SEC website